Outcome of Board Meeting held on May 18, 2026 - Press Release
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Strides Pharma reported strong FY26 results with EBITDA at ₹9,253m (up 15.3% YoY) and Operational PAT at ₹5,181m (up 50.3% YoY). Total revenue stood at ₹48,587m, growing 6.4% YoY. The company delivered EBITDA margin expansion of 140bps to 19.0%, driven by Ex-US markets growing 21% YoY while the US market grew a modest 2% YoY. Gross margin expanded 310bps YoY to 59.7%. Net Debt to EBITDA improved to 1.55x from 1.9x in FY25. RoCE increased to 15.8% from 14.9%. The Board recommended a dividend of ₹5 per share.
Strides delivered robust profitability with 50% PAT growth and margin expansion, signaling strong operating leverage. The Ex-US market growth outpacing the US market signals a successful diversification strategy. The improving leverage ratio and higher RoCE are positives for shareholders.